The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1541
February 26, 2018
View Complete Issue         Table of Contents 2019 
Issue 1541
Subscribers: Log in to read full issue.  Not a subscriber?  Subscribe or purchase issue.
Benralizumab (Fasenra) for Severe Eosinophilic Asthma
February 26, 2018 (Issue: 1541)
The FDA has approved benralizumab (Fasenra – AstraZeneca), a humanized monoclonal antibody selective for the interleukin-5 (IL-5) receptor, for add-on maintenance treatment of severe asthma in patients ≥12 years old with an eosinophilic...more
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this issue?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App
  • FREE online per issue CME/CE
Purchase this issue:
Title: Issue 1541
 


Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.